Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
J1013: A Phase II Study of Gemcitabine and nab-Paclitaxel in Combination with GDC-0449 (Hedgehog Inhibitor) in Patients with Previously Untreated Metastatic Adenocarcionoma of the Pancreas
Protocol Number:
J1013
Phase:
Phase II
Physician:
Daniel Laheru
Purpose:
To determine the benefits of using GDC-0449(Hedgehog inhibitor) in combination with Gemcitabine and nab-Paclitaxel in pateints with Metastatic Pancreatic Cancer.
Eligibility:
Metastatic pancreatic cancer-No previous radiation, surgery or chemotherapy or investigational therapy for treatment of metastatic disease- radiation, chemotherapy or investigation therapy in the adjuvant setting should be completed 3 weeks before starting treatment- good physical condition with good blood counts and organ function-must be willing to use 2 typse of birth control-patients must not be on therapuetic coumadin
Treatment:
Patients will receive combination Gemcitabine + nab-Paclitaxel infused(IV) over 30 minutes each, once a week for 3 weeks with 1 week off (4 weeks or 1 cycle)- Cycle 2 Day will be the first dose of GDC-0449 to be taken daily for 28 days.
Population:
Adult
Last Update
07/29/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer